

2018 JAN -8 AM 11:23  
OFFICE OF THE  
SECRETARY

Amendment in the Nature of a Substitute  
(B22-106 ENGROSSED ORIGINAL)  
Councilmembers Charles Allen and Vincent C. Gray  
January 9, 2018

A BILL

22-106

IN THE COUNCIL OF THE DISTRICT OF COLUMBIA

To amend the District of Columbia Health Occupations Revision Act of 1985 to allow pharmacists to prescribe and dispense certain contraceptives pursuant to established protocols; to amend the Women's Health and Cancer Rights Federal Law Conformity Act of 2000 to require insurers to cover certain health care services without cost-sharing, to require that insurers authorize dispensing of up to a 12-month supply of a pharmacist-prescribed and dispensed self-administered contraceptive, to provide to certain employers a religious exemption from or accommodation for the coverage of contraceptive products and services, and to require insurers to provide information regarding coverage to enrollees and potential enrollees.

BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Defending Access to Women's Health Care Services Amendment Act of 2017".

Sec. 2. The District of Columbia Health Occupations Revision Act of 1985, effective March 25, 1986 (D.C. Law 6-99; D.C. Official Code § 3-1201.01 *et seq.*), is amended as follows:

(a) Section 101 (D.C. Official Code § 3-1201.01) is amended by adding new paragraphs (9A) and (12B) to read as follows:

34 “(9A) “Long-Acting Reversible Contraceptive” means a contraceptive that  
35 requires administering less than once per cycle or month.

36 “(12B) “Self-administered hormonal contraceptive” means a contraceptive  
37 containing hormones approved by the U.S. Food and Drug Administration that is administered  
38 by the patient orally, transdermally, or vaginally.”.

39 (b) Section 102(11)(A) (D.C. Official Code § 3-1201.02(11)(A)) is amended by striking  
40 the phrase “the compounding, dispensing, and labeling of drugs and devices;” and inserting the  
41 phrase “the compounding, dispensing, and labeling of drugs and devices, including self-  
42 administered hormonal contraceptives;” in its place.

43 (c) Section 208 (D.C. Official Code § 3-1202.08) is amended by adding a new subsection  
44 (g-1) to read as follows:

45 “(g-1)(1) An individual licensed to practice pharmacy pursuant to this act ~~shall~~ may  
46 prescribe and dispense up to a 12-month supply of self-administered hormonal contraceptives if  
47 certified to do so by the Board and pursuant to a written protocol established by the Board and  
48 the Board of Medicine under paragraph (2) of this subsection.

49 “(2) The Board and the Board of Medicine shall jointly develop and issue  
50 regulations establishing protocols for the prescription and dispensation of self-administered  
51 hormonal contraceptives. The protocols shall include the following requirements:

52 “(A) If the pharmacist has not already undergone training as part of the  
53 pharmacist’s formal educational program, that the pharmacist complete a training program

approved by the Board and the Board of Medicine for prescribing and dispensing self-administered hormonal contraceptives;

“(B) That the patient use a self-screening tool developed by the Board and the Board of Medicine that will identify patient risk factors for the use of self-administered hormonal contraceptives, based on the current United States Medical Eligibility Criteria for Contraceptive Use developed by the Centers for Disease Control and Prevention;

“(C) That a pharmacist may determine, based on the results of the self-screening tool described in subparagraph (B) of this paragraph, when it is not safe to dispense a 12-month supply of self-administered hormonal contraceptives;

“(D) That when a self-administered hormonal contraceptive is prescribed and dispensed, the patient shall be provided, in a manner that ensures patient confidentiality, appropriate counseling and information on the product furnished, including dosage, effectiveness, potential side effects, safety, the importance of receiving recommended preventive health screenings, and that a self-administered hormonal contraceptive does not protect against sexually transmitted infections;

“(E) That the pharmacist refer the patient to the patient’s primary care provider or reproductive health provider or, if the patient does not have a primary care provider or reproductive health provider, to a nearby clinic, upon prescribing and dispensing a self-administered hormonal contraceptive pursuant to the subsection or if it is determined that the use of a self-administered hormonal contraceptive is not recommended; and



74 “(F) That the pharmacist provide the patient with written material,  
75 developed by the Board and the Department of Health, describing all FDA-approved  
76 contraceptives, including Long-Acting Reversible Contraceptives.

77 “(3) The reimbursement to a pharmacist from an individual health plan or group  
78 health plan, and health insurance coverage through Medicaid or the D.C. Healthcare Alliance  
79 program for services required by regulations issued pursuant to paragraph (2) of this subsection,  
80 shall be limited to an amount determined through regulation by the Department of Insurance,  
81 Securities, and Banking.

82 “(4) This section does not alter the requirement under federal and District of  
83 Columbia law that the provision of contraceptive drugs, devices, products, and services,  
84 including contraceptive counseling, shall be covered without cost-sharing, which includes the  
85 prescribing and provision of contraceptives by any in-network provider, including a pharmacist.

86 “(5) The Board shall maintain a list of all pharmacists certified to prescribe and  
87 dispense contraception without a prescription, including the location of the pharmacy where the  
88 pharmacist currently practices, and make that list readily accessible to the public.

89 “(6) A pharmacy shall display in stores and online a list of the times during which  
90 a pharmacist certified to prescribe and dispense contraception is available.

91 “(7) The Board shall provide to all licensed pharmacists annual notice of the  
92 requirements of this subsection, including opportunities for training.

93 “(9) The Board and the Board of Medicine, in consultation with the American



Congress of Obstetricians and Gynecologists, shall jointly develop and promulgate regulations to implement the provisions of this subsection by January 1, 2019.”.

Sec. 3. The Women's Health and Cancer Rights Federal Law Conformity Act of 2000, effective April 3, 2001 (D.C. Law 13-254; D.C. Official Code § 31-3831 *et seq.*), is amended as follows:

(a) Section 5a (D.C. Official Code § 31-3834.01) is amended as follows:

(1) Subsection (a) is amended by striking the phrase “Medicaid shall provide benefits that allow for the dispensing of up to a 12-month supply of a covered prescription contraceptive at one time.” and inserting the phrase “Medicaid and the D.C. Healthcare Alliance Program shall provide coverage for a supply of contraceptives intended to last over the course of a 12-month period, that shall be dispensed all at once or over the course of the 12 months at the patient’s election, including for over-the-counter contraceptives and contraceptives obtained from a licensed pharmacist without a prescription pursuant to section 208(g-1) of the District of Columbia Health Occupations Revision Act of 1985, effective March 25, 1986 (D.C. Law 6-99; D.C. Official Code § 3-1202.08(g-1)), provided that the DC Healthcare Alliance program shall not be required to provide coverage for a supply of contraceptives intended to last longer than the period of recertification for the DC Healthcare Alliance. The costs of any consultation by the pharmacist shall also be covered.” in its place.

(2) Subsection (c) is repealed.

(b) A new section 5b is added to read as follows:

114 “Sec. 5b. Coverage of preventive health services.

115 “(a) An individual health plan or group health plan and health insurance coverage  
116 through Medicaid or the D.C. Healthcare Alliance program shall provide coverage for, and shall  
117 not impose any cost-sharing requirements on, women for the following preventive health  
118 services and products:

119 “(1)(A) Breast cancer screening;

120 “(B) Breast feeding support, services, and supplies;

121 “(C) Screening for cervical cancer, including HPV testing;

122 “(D) Screening for gestational diabetes;

123 “(E) Screening and counseling for HIV;

124 “(F) Screening and counseling for interpersonal and domestic violence;

125 “(G) Screening and counseling for sexually-transmitted diseases;

126 “(H) Screening and counseling for Hepatitis B and C;

127 “(I) Well-woman preventive visits, including visits to obtain necessary  
128 preventive care, preconception care, and prenatal care;

129 “(J) Folic acid supplementation;

130 “(K) Breast cancer chemoprevention counseling and preventive  
131 medications;

132 “(L) Risk assessment and genetic counseling and testing using the Breast  
133 Cancer Risk Assessment tool approved by the National Cancer Institute; and

134 “(M) Rh incompatibility screening;

135 “(2) Those evidence-based items or services that have in effect a rating of “A” or  
136 “B” in the recommendations of the U.S. Preventive Services Task Force as of September 19,  
137 2017; and

138 “(3) Any additional health services or products identified ~~in a Mayor’s order~~ by  
139 rules issued pursuant to subsection (c) of this section.

140 “(b) A health insurer and health insurance coverage through Medicaid or the D.C.  
141 Healthcare Alliance program offering health insurance coverage exclusively for prescription  
142 drugs shall provide coverage for, and shall not impose any cost-sharing requirements for women  
143 for, contraceptives, including over-the-counter contraceptives and contraceptives prescribed and  
144 dispensed by a pharmacist, and the following:

145 “(1) Those evidence-based prescription-drug items or related services that have in  
146 effect a rating of “A” or “B” in the recommendations of the United States Preventive Services  
147 Task Force as of September 19, 2017; and

148 “(32) Any additional contraceptive drug products identified ~~in a Mayor’s order~~ by  
149 rules issued pursuant to subsection (c) of this section.

150 “(c)(1) Within 30 days of the effective date of the Defending Access to Women’s Health  
151 Care Services Amendment Act of 2017, passed on 2<sup>nd</sup> reading on January 9, 2018 (Enrolled  
152 version of Bill 22-106), the Mayor, pursuant to Title I of the District of Columbia Administrative  
153 Procedure Act, approved October 21, 1968 (82 Stat. 1204; D.C. Official Code § 2-501 et seq.),



154 shall ~~publish in the D.C. Register an order~~ issue rules listing the items and services defined in  
155 subsections (a) and (b) of this section to be covered without imposing any cost-sharing  
156 requirements.

157 “(2) The Mayor shall amend the ~~order~~ rules required by this subsection as necessary  
158 to:

159 “(A) Include additional preventive services or products for women or  
160 expansions of covered preventive services or products for women identified by the United States  
161 Preventive Services Task Force or the Health Resources and Services Administration of the  
162 United States Department of Health and Human Services after September 19, 2017; and

163 “(B) Remove items or services defined in subsections (a) and (b) of this  
164 section that a federal agency determines to pose a significant safety concern, consistent with the  
165 requirements of 45 C.F.R. § 147.130(b).”.

166 (c) A new section 5c is added to read as follows:

167 “Sec. 5c. Coverage of additional preventive health services

168 “(a) Health insurance coverage through Medicaid or the DC Healthcare Alliance  
169 program shall also provide coverage for and shall not impose any cost-sharing requirements for  
170 the following:

171 “(1) Voluntary sterilization procedures for women;

172 “(2)(A) All contraceptive products approved by the Food and Drug  
173 Administration, including emergency contraception

174                   “(B) If there is a therapeutic equivalent of an FDA-approved contraceptive  
175 drug, device, or product, coverage shall also include either the original FDA-approved  
176 contraceptive drug, device, or product or at least one of its therapeutic equivalents, without  
177 imposing any cost-sharing requirements.

178                   “(C) If the covered contraceptive drug, device, or product is deemed  
179 medically inadvisable by a provider, the health insurer shall defer to the determination and  
180 judgment of the attending provider and provide coverage for the alternative prescribed  
181 contraceptive drug, device, or product without imposing any cost-sharing requirements;

182                   “(D) Nothing in this section shall prohibit a health insurer from requiring  
183 the use of a generic prescription drug when providing coverage for preventive contraceptive  
184 services, so long as such health insurer:

185                   “(i) Has a process for a member to seek medically necessary  
186 coverage of a covered brand name contraceptive drug as determined by the member’s  
187 prescribing provider; and

188                   “(ii) Provides coverage for a brand name contraceptive drug when  
189 there is no generic substitute available in the market.

190                   “(3) Contraceptive services including consultation with a pharmacist, patient  
191 education, and counseling on contraception; and

192 “(4) Follow-up services related to the drugs, devices, products, and procedures  
193 covered under this section, including management of side effects, counseling for continued  
194 adherence, and device insertion and removal.

195 “(b) Beginning on January 1, 2019 or the next date when carrier forms are approved,  
196 whichever is earlier, an individual health plan or group health plan shall also provide coverage  
197 for and shall not impose any cost-sharing requirements for all products and services listed in  
198 subsection (a) of this section.”.

199 (d) A new section 5d is added to read as follows:

200 “Sec. 5d. Religious exemption and accommodation.

201 “(a)(1) A religious employer organized and operating as a nonprofit entity and referred to  
202 in section 6033(a)(3)(A)(i) or (iii) of the Internal Revenue Code of 1986 may be exempt from any  
203 requirement to cover contraceptive products and services under section 5b and D.C. Official Code  
204 § 31-3834.01.

205 “(2) A religious employer claiming an exemption under this subsection shall  
206 provide its employees and prospective employees reasonable and timely notice of the exemption  
207 prior to enrollment with the plan, and the notice shall list the contraceptive products and services  
208 for which the employer does not provide coverage.

209 “(3) Nothing in this section shall be construed to allow for the exclusion of coverage  
210 for contraceptive supplies as prescribed by a provider, acting within his or her scope of practice,  
211 for reasons other than contraceptive purposes, such as decreasing the risk of ovarian cancer or



212 eliminating symptoms of menopause, or for contraception that is necessary to preserve the life or  
213 health of an enrollee.

214 “(b)(1) Nothing in this act shall be construed to require an employer to provide coverage  
215 for contraceptive products or services through its employer-based group health plan, provided  
216 that the employer has ~~received~~ provided to its group health insurance issuer a notice of request  
217 for accommodation, in a form and manner specified by the Mayor, and the insurer has certified  
218 that the employer meets the requirements of subsection (c) of this section ~~from the District of~~  
219 ~~Columbia Department of Health.~~

220 “(2) Beginning on January 1, 2019, and on a quarterly basis thereafter, a group  
221 health insurance issuer shall notify the Department of Insurance, Securities, and Banking which  
222 employers have been granted an accommodation pursuant to subsection (c) of this section.

223 “(23) An employer that receives an ~~notice of~~ accommodation pursuant to  
224 subsection (c) of this section ~~from the Department of Health~~ shall provide, through its employer-  
225 based plan, coverage for contraceptive supplies as prescribed and dispensed by a provider, acting  
226 within her or her scope of practice, for reasons other than contraceptive purposes, such as  
227 decreasing the risk of ovarian cancer or eliminating symptoms of menopause, and for  
228 contraception that is necessary to preserve the life or health of an enrollee.

229 “(c) ~~The Department of Health~~ A group health insurance issuer shall ~~issue a notice of~~  
230 provide an employer with an accommodation to the requirements of this act upon receipt of a  
231 self-certification, in a form and manner specified by the Mayor, that the employer is:

232 “(1) A nonprofit organization that holds itself out as a religious organization and  
233 objects to covering some or all of the contraceptive services on account of its sincerely held  
234 religious beliefs; or

235 “(2) A closely-held for-profit entity, provided that its highest governing body  
236 (such as its board of directors, board of trustees, or owners, if managed directly by its owners)  
237 has adopted a resolution or similar action establishing that it objects to covering some or all of  
238 the contraceptive services on account of the owners' sincerely held religious beliefs.

239 ~~“(d)(1) An employer seeking an accommodation pursuant to subsection (b) shall provide~~  
240 ~~to its group health insurance issuer a copy of the notice of accommodation.~~

241 ~~\_\_\_\_\_“(2) Upon receipt of a valid notice of request for accommodation that conforms to~~  
242 ~~the requirements of subsection (c) of this section, a group health insurance issuer shall:~~

243 ~~\_\_\_\_\_“(A1) Exclude contraceptive coverage from the group health insurance~~  
244 ~~coverage provided in connection with the employer’s group health plan; and~~

245 ~~\_\_\_\_\_“(B2) Provide separate payments for any contraceptive products or~~  
246 ~~services required to be covered under this sections 5a and 5b without imposing any cost-sharing~~  
247 ~~requirements or any other fee directly or indirectly on the employer, the group health plan, or~~  
248 ~~plan participants of beneficiaries.~~

249 ~~“(3)(A) A group health insurance issuer that provides payment for contraceptive~~  
250 ~~services pursuant to paragraph (2)(B) of this subsection shall provide coverage for all products~~  
251 ~~and services required by this act and shall not impose any cost-sharing requirements or impose~~

252 any other fee directly or indirectly on the employer, the group health plan, or plan participants or  
253 beneficiaries.

254 ~~“(B) The group health insurance issuer shall segregate premium revenue~~  
255 ~~collected from the employer from monies used to provide payments for contraceptive products or~~  
256 ~~services pursuant to paragraph (2)(B) of this subsection.~~

257 “(d) For purposes of this section, the term “closely-held for-profit entity” means an entity  
258 that:

259 “(1) Is not a nonprofit entity;

260 “(2) Has no publicly traded ownership interests of any class of common equity  
261 securities required to be registered under section 12 of the Securities Exchange Act of 1934; and

262 “(3) Has more than 50 percent of the value of its ownership interest owned  
263 directly or indirectly by five or fewer individuals, or has an ownership structure that is  
264 substantially similar thereto, as of the date of the entity's self-certification pursuant to subsection  
265 (c) of this section.”.

266 (e) A new section 5e is added to read as follows:

267 “Sec. 5e. Notice of rights to healthcare coverage.

268 “(a) An insurer that is subject to sections 5a or 5b shall make readily accessible to  
269 enrollees and potential enrollees information regarding:

270 “(1) Full and accurate information relevant to coverage and cost-sharing for  
271 contraceptive services by each health insurance plan, including an explanation of an insured's



272 financial responsibility for payment of premiums, coinsurance, copayments, deductibles and any  
273 other charges;

274 “(2) The coverage of other services, drugs, devices, products and procedures  
275 described in sections 5a and 5b; and

276 “(3) The right to receive up to a 12-month supply of contraception from a licensed  
277 pharmacist without a prescription or cost-sharing requirements.

278 “(b)(1) The insurer shall provide the information described in subsection (a) of this  
279 section in a consumer-friendly format:

280 “(A) That can be viewed on the insurer’s public website through a clearly  
281 identifiable link or tab without requiring an individual to create or access an account or enter a  
282 policy or contract number;

283 “(B) By email or letter within 14 days after a request by an enrollee; and

284 “(C) Within one year of the effective date of the Defending Access to  
285 Women’s Health Care Services Amendment Act of 2017, passed on 2<sup>nd</sup> reading on January 9,  
286 2018, (Enrolled version of Bill 22-106), or whenever written materials are reprinted, whichever is  
287 sooner, in written materials that explain benefits or coverage that are provided to enrollees and  
288 potential enrollees, including in an addendum to a summary of benefits and coverage.

289 “(2) This subsection shall be construed consistently with section 2715 of the  
290 Public Health Services Act, as amended by the Patient Protection and Affordable Care Act,  
291 approved March 23, 2010 (124 Stat. 132; 42 U.S.C. § 300gg-15).

292 “(c) The Department of Insurance, Securities and Banking shall provide yearly notice to  
293 health insurers operating in the District of Columbia of their obligation to provide coverage for  
294 services, drugs, devices, products and procedures described in sections 5a and 5b.”.

295 Sec. 4. Applicability.

296 (a) Sections 2(c) shall apply upon the date of inclusion of its fiscal effect in an approved  
297 budget and financial plan.

298 (b) The Chief Financial Officer shall certify the date of the inclusion of the fiscal effect in  
299 an approved budget and financial plan, and provide notice to the Budget Director of the Council  
300 of the certification.

301 (c)(1) The Budget Director shall cause the notice of the certification to be published in  
302 the District of Columbia Register.

303 (2) The date of publication of the notice of the certification shall not affect the  
304 applicability of this section.

305 Sec. 5. Fiscal impact statement.

306 The Council adopts the fiscal impact statement in the committee report as the fiscal  
307 impact statement required by section 4a of the General Legislative Procedures Act of 1975,  
308 approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).

309 Sec. 6. Effective date.

310 This act shall take effect following approval by the Mayor (or in the event of veto by the  
311 Mayor, action by the Council to override the veto), a 30-day period of congressional review as

312 provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December  
313 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of  
314 Columbia Register.






**OFFICE OF THE GENERAL COUNSEL**

Council of the District of Columbia  
1350 Pennsylvania Avenue NW, Suite 4  
Washington, DC 20004  
(202) 724-8026

**MEMORANDUM**

**TO:** Councilmember Charles Allen

**FROM:** John Hoellen, Deputy General Counsel 

**DATE:** January 9, 2018

**RE:** Legal sufficiency determination for Amendment in the Nature of a Substitute to Bill 22-106, the Defending Access to Women's Health Care Services Amendment Act of 2017

---

The measure is legally and technically sufficient for Council consideration.

This Amendment in the Nature of a Substitute ("ANS") to Bill 22-106, the Engrossed version of the Defending Access to Women's Health Care Services Amendment Act of 2017, clarifies that the list of health services and products that the bill requires insurers to cover without cost-sharing shall be issued by rulemaking. Additionally, the ANS shifts the responsibility for processing requests for a religious-based accommodation from the Department of Health to insurance providers, and imposes a requirement upon insurers to notify the Department of Insurance, Securities, and Banking on a quarterly basis which employers have been granted an accommodation. Finally, the ANS removes a requirement that insurers segregate premium revenue collected from employers that have received an accommodation to the bill's requirements from the monies used to provide alternate coverage for an employee's contraceptives.

I am available if you have any questions.




**COUNCIL OF THE DISTRICT OF COLUMBIA**  
**Office of the Budget Director**



Jennifer Budoff  
Budget Director

**FISCAL IMPACT STATEMENT**

**TO:** The Honorable Phil Mendelson  
Chairman, Council of the District of Columbia

**FROM:** Jennifer Budoff - Budget Director 

**DATE:** January 8, 2018

**SHORT TITLE:** B22-106 "Defending Access to Women's Health Care Services Amendment Act of 2017"

**TYPE:** Amendment in the Nature of a Substitute

**REQUESTING OFFICE:** Councilmember Charles Allen

---

**Conclusion**

This amendment in the nature of a substitute does not have an impact on the District's budget or the financial plan, because there is no cost associated with implementing this legislation. However, the underlying bill remains subject in inclusion in the District's budget and financial plan.<sup>1</sup>

**Background**

This amendment in the nature of a substitute makes three substantive changes to bill. First, as drafted the bill requires the Mayor to publish in the D.C. Register a mayor's order listing health services and products that the bill requires insurers to cover without cost-sharing. The ANS changes this process to a formal rulemaking. Second, the ANS shifts the burden of processing requests for a religious-based accommodation from the Department of Health to insurance providers. The ANS requires insurers to notify the Department of Insurance, Securities, and Banking quarterly which employers have been granted an accommodation; this will create a public record of requests for accommodations, which does not currently exist at the local level. Third, the ANS removes a requirement that insurers segregate premium revenue collected from employers that have received an accommodation to the bill's requirements from the monies used to provide alternate coverage for employee's contraceptives.

---

<sup>1</sup> Office of the Chief Financial Officer, Fiscal Impact Statement – Bill 22-106 Defending Access to Women's Health Care Services Amendment Act of 2017 (November 2, 2017), available at [http://app.cfo.dc.gov/services/fiscal\\_impact/search.asp](http://app.cfo.dc.gov/services/fiscal_impact/search.asp) (last visited January 8, 2018).



**Analysis of Impact on Spending**

This emergency has no impact on spending.

**Analysis of Impact on Revenue**

This emergency has no impact on revenue.